A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma

Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis. 1993;22:5–10.

Wągrowska-Danilewicz M, Danilewicz M. Glomerulonephritis associated with malignant disease of non-renal origin. A report of three cases and a review of the literature. Pol J Pathol. 1995;46:195–8.

Ross JH, McGinty F, Brewer DG. Penicillamine nephropathy. Nephron. 1980;26:184–6.

Nagahama K, Matsushita H, Hara M, et al. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39:706–12.

Sturgill BC, Shearlock KT. Membranous glomerulopathy and nephrotic syndrome after captopril therapy. JAMA. 1983;250:2343–5.

Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005;16:1188–94.

Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7.

Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.

Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82:797–804.

Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58:57–62.

Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68:302–10.

Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transpl. 2004;19:574–9.

Oliveira DB. Membranous nephropathy: an IgG4-mediated disease. Lancet. 1998;351:670–1.

Qu Z, Liu G, Li J, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transpl. 2012;27:1931–7.

Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7:85–95.

Jhaveri KD, Shah HH, Calderon K, et al. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013;84:34–44.

Masutani K, Fujisaki K, Maeda H, et al. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol. 2008;12:398–402.

Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28–32.

Mori H, Hhno Y, Ito F, et al. Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib. Jpn J Clin Oncol. 2010;40:263–6.

Wan HL, Yao NS. Acute renal failure associated with gefitinib therapy. Lung. 2006;184:249–50.

Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol. 2004;22:2504–5.

Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56:355–77.

Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol. 2003;23:400–5.

Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154–60.

Ito C, Fujii H, Ogura M, et al. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer. J Oncol Pharm Pract. 2013;19:265–8.

Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–36.

Hayman SR, Leung N, Grande JP, et al. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14:285–94.

Kijima T, Shimizu T, Nonen S, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol. 2011;29:588–90.